<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) are at a high risk of developing atherosclerotic complications </plain></SENT>
<SENT sid="1" pm="."><plain>Conversely, individuals with primary <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> have an increased prevalence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) and antibodies to oxidized <z:chebi fb="2" ids="39026">low-density lipoproteins</z:chebi> (ox-<z:chebi fb="15" ids="39026">LDL</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>Several studies suggest that these two antibody populations may in fact overlap, although it is unclear how aPL contribute to pathogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we characterized an IgG monoclonal aPL and assessed its ability to modulate <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> receptor-deficient (LDLR(-/-)) mice </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The <z:chebi fb="0" ids="28494">cardiolipin</z:chebi>-reactive monoclonal antibody FB1 was obtained from an (NZW x BXSB)F(1) mouse, a strain with APS features that make it prone to fatal <z:hpo ids='HP_0001658'>myocardial infarctions</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Using an enzyme-linked immunosorbent assay, we investigated the binding of this antibody to <z:chebi fb="0" ids="16247">phospholipid</z:chebi> and <z:chebi fb="15" ids="39026">LDL</z:chebi> antigens </plain></SENT>
<SENT sid="6" pm="."><plain>We also passively administered FB1 to <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>-prone mice to determine its effect on atherogenesis </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In contrast to earlier studies of aPL that were specific for oxidized forms of <z:chebi fb="15" ids="39026">LDL</z:chebi>, FB1 cross-reacted with both native <z:chebi fb="15" ids="39026">LDL</z:chebi> and ox-<z:chebi fb="15" ids="39026">LDL</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>In vivo, passive administration of FB1 significantly reduced plaque formation in <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>-prone LDLR(-/-) mice </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: These results indicate that some aPL may play a protective role in atherogenesis and suggest a novel approach to the prevention of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
</text></document>